Because CXCR3 activity is required for tumor eradication in this model, the prognostic effect CXCL9 in HNSCC previously reported should be evaluated based on the context of where CXCR3 is expressed; CXCL9- or CXCL10-positive tumors with CXCR3 expressed on infiltrating immune cells may be indicative of a therapeutic response. Here, CXCR3 is linked to neoplasm.